Sarcopenia is associated with severe liver fibrosis in patients with non‐alcoholic fatty liver disease

Sarcopenia recognises insulin resistance and obesity as risk factors, and is frequently associated with cardiometabolic disorders, including non‐alcoholic fatty liver disease (NAFLD).

[1]  M. Chang,et al.  Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. , 2017, Journal of hepatology.

[2]  Manuela Merli,et al.  Sarcopenia from mechanism to diagnosis and treatment in liver disease. , 2016, Journal of hepatology.

[3]  L. N. Valenti,et al.  Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis , 2015, Disease Models & Mechanisms.

[4]  Q. Xiao,et al.  Effect of Angiotensin-Converting Enzyme Inhibitors on Physical Function in Elderly Subjects: A Systematic Review and Meta-Analysis , 2015, Drugs & Aging.

[5]  E. Kang,et al.  Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008-2011). , 2015, Journal of hepatology.

[6]  E. Bjornsson,et al.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. , 2015, Gastroenterology.

[7]  M. Sawyer,et al.  Inclusion of Sarcopenia Within MELD (MELD-Sarcopenia) and the Prediction of Mortality in Patients With Cirrhosis , 2015, Clinical and Translational Gastroenterology.

[8]  K. Thomopoulos,et al.  Impact of muscle wasting on survival in patients with liver cirrhosis. , 2015, World journal of gastroenterology.

[9]  A. Mugelli,et al.  Pharmacological perspectives in sarcopenia: a potential role for renin-angiotensin system blockers? , 2015, Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases.

[10]  Mats Fredrikson,et al.  Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up , 2015, Hepatology.

[11]  M. Shimizu,et al.  Sarcopenia impairs prognosis of patients with liver cirrhosis. , 2015, Nutrition.

[12]  F. Tacke,et al.  Roles for chemokines in liver disease. , 2014, Gastroenterology.

[13]  C. Cooper,et al.  ACE inhibitors, statins and thiazides: no association with change in grip strength among community dwelling older men and women from the Hertfordshire Cohort Study. , 2014, Age and ageing.

[14]  D. Tricarico,et al.  Effects of the antidiabetic drugs on the age-related atrophy and sarcopenia associated with diabetes type II. , 2014, Current diabetes reviews.

[15]  H. J. Yoo,et al.  Relationship between sarcopenia and nonalcoholic fatty liver disease: The Korean Sarcopenic Obesity Study , 2014, Hepatology.

[16]  The Lancet Diabetes & Endocrinology.  Sarcopenia: a fate worth challenging. , 2014, The lancet. Diabetes & endocrinology.

[17]  Stefano Cabras,et al.  Accuracy of Specific BIVA for the Assessment of Body Composition in the United States Population , 2013, PloS one.

[18]  G. Sesti,et al.  Insulin-like growth factor-I, inflammatory proteins, and fibrosis in subjects with nonalcoholic fatty liver disease. , 2013, The Journal of clinical endocrinology and metabolism.

[19]  G. Sergi,et al.  The potential of classic and specific bioelectrical impedance vector analysis for the assessment of sarcopenia and sarcopenic obesity , 2012, Clinical interventions in aging.

[20]  M. Sawyer,et al.  Muscle wasting is associated with mortality in patients with cirrhosis. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[21]  B. Spiegelman,et al.  A PGC1α-dependent myokine that drives browning of white fat and thermogenesis , 2012, Nature.

[22]  Shingo,et al.  A PGC1-\(\alpha\)-dependent Myokine that Drives Brown-fat-like Development of White Fat and Thermogenesis , 2012 .

[23]  G. Sergi,et al.  Efficacy of specific bioelectrical impedance vector analysis (BIVA) for assessing body composition in the elderly , 2012, The journal of nutrition, health & aging.

[24]  A. Craxì,et al.  Hyperuricemia is associated with histological liver damage in patients with non‐alcoholic fatty liver disease , 2011, Alimentary pharmacology & therapeutics.

[25]  B. Gao,et al.  Inflammation‐associated interleukin‐6/signal transducer and activator of transcription 3 activation ameliorates alcoholic and nonalcoholic fatty liver diseases in interleukin‐10–deficient mice , 2011, Hepatology.

[26]  Sandrine Andrieu,et al.  Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. , 2011, Journal of the American Medical Directors Association.

[27]  Douglas E Schaubel,et al.  Sarcopenia and mortality after liver transplantation. , 2010, Journal of the American College of Surgeons.

[28]  A. Suzuki,et al.  Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease , 2010, Hepatology.

[29]  J. Michel,et al.  Understanding sarcopenia as a geriatric syndrome , 2010, Current opinion in clinical nutrition and metabolic care.

[30]  J. Baeyens,et al.  European working group on sarcopenia in older people. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people , 2010 .

[31]  S. Grundy,et al.  Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International As , 2009, Circulation.

[32]  A. Craxì,et al.  Non-alcoholic fatty liver disease pathogenesis: the present and the future. , 2009, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[33]  G. Targher,et al.  Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. , 2007, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[34]  G. Bedogni,et al.  Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study , 2005, Hepatology.

[35]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[36]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[37]  G. Leandro,et al.  Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. , 2003, Journal of hepatology.

[38]  R. Trio,et al.  Impedance vector distribution by body mass index and conventional bioelectrical impedance analysis in obese women. , 2003, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[39]  P. Raskin,et al.  Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.

[40]  Robert Ross,et al.  Low Relative Skeletal Muscle Mass (Sarcopenia) in Older Persons Is Associated with Functional Impairment and Physical Disability , 2002, Journal of the American Geriatrics Society.

[41]  O. Selberg,et al.  Norms and correlates of bioimpedance phase angle in healthy human subjects, hospitalized patients, and patients with liver cirrhosis , 2002, European Journal of Applied Physiology.

[42]  W. Frontera,et al.  Aging of skeletal muscle: a 12-yr longitudinal study. , 2000, Journal of applied physiology.

[43]  W. Chumlea,et al.  Bioelectric impedance phase angle and body composition. , 1988, The American journal of clinical nutrition.